Literature DB >> 27499999

Time to get real: critical and imperative change required in evidence evaluation.

David B Price1.   

Abstract

Year:  2016        PMID： 27499999      PMCID： PMC4958775          DOI： 10.21037/jtd.2016.07.10

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  8 in total

1.  De Testimonio: on the evidence for decisions about the use of therapeutic interventions.

Authors:  Michael Rawlins
Journal:  Clin Med (Lond)       Date:  2008-12       Impact factor: 2.659

2.  An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice.

Authors:  Helen K Reddel; D Robin Taylor; Eric D Bateman; Louis-Philippe Boulet; Homer A Boushey; William W Busse; Thomas B Casale; Pascal Chanez; Paul L Enright; Peter G Gibson; Johan C de Jongste; Huib A M Kerstjens; Stephen C Lazarus; Mark L Levy; Paul M O'Byrne; Martyn R Partridge; Ian D Pavord; Malcolm R Sears; Peter J Sterk; Stuart W Stoloff; Sean D Sullivan; Stanley J Szefler; Mike D Thomas; Sally E Wenzel
Journal:  Am J Respir Crit Care Med       Date:  2009-07-01       Impact factor: 21.405

3.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.

Authors:  Gordon H Guyatt; Andrew D Oxman; Gunn E Vist; Regina Kunz; Yngve Falck-Ytter; Pablo Alonso-Coello; Holger J Schünemann
Journal:  BMJ       Date:  2008-04-26

4.  Integrating real-life studies in the global therapeutic research framework.

Authors:  Nicolas Roche; Helen K Reddel; Alvar Agusti; Eric D Bateman; Jerry A Krishnan; Richard J Martin; Alberto Papi; Dirkje Postma; Mike Thomas; Guy Brusselle; Elliot Israel; Cynthia Rand; Alison Chisholm; David Price
Journal:  Lancet Respir Med       Date:  2013-12-02       Impact factor: 30.700

Review 5.  Beclomethasone for asthma in children: effects on linear growth.

Authors:  P J Sharek; D A Bergman
Journal:  Cochrane Database Syst Rev       Date:  2000

6.  How representative are clinical study patients with asthma or COPD for a larger "real life" population of patients with obstructive lung disease?

Authors:  Kjetil Herland; Jan-Petter Akselsen; Ole Henning Skjønsberg; Leif Bjermer
Journal:  Respir Med       Date:  2005-01       Impact factor: 3.415

7.  The Brussels Declaration: the need for change in asthma management.

Authors:  S Holgate; H Bisgaard; L Bjermer; T Haahtela; J Haughney; R Horne; A McIvor; S Palkonen; D B Price; M Thomas; E Valovirta; U Wahn
Journal:  Eur Respir J       Date:  2008-12       Impact factor: 16.671

Review 8.  Real-world research and its importance in respiratory medicine.

Authors:  David Price; Guy Brusselle; Nicolas Roche; Daryl Freeman; Alison Chisholm
Journal:  Breathe (Sheff)       Date:  2015-03
  8 in total
  2 in total

1.  Modelling the Cost-Effectiveness of Indacaterol/Glycopyrronium versus Salmeterol/Fluticasone Using a Novel Markov Exacerbation-Based Approach.

Authors:  Bhavesh Lakhotia; Ronan Mahon; Florian S Gutzwiller; Andriy Danyliv; Ivan Nikolaev; Praveen Thokala
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2020-04-16

Review 2.  Corticosteroid plus β2-agonist in a single inhaler as reliever therapy in intermittent and mild asthma: a proof-of-concept systematic review and meta-analysis.

Authors:  Gang Wang; Xin Zhang; Hong Ping Zhang; Lei Wang; De Ying Kang; Peter J Barnes; Gang Wang
Journal:  Respir Res       Date:  2017-12-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.